Skip to main content

Table 2 Seroreactivity in association with benign condylomatous warts: Cumulative antibody responses to low risk (HPV-6, -11) or high risk (HPV-16, -18, -31) VLPs in HIV-positive versus HIV-negative men

From: High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study

Men with warts: HIV-positive (n = 25, HIV-negative (n = 55)
  including 9 homosexuals)  
antibodies to low risk HPV 10 (40 %)+ 14 (25.4 %)+
antibodies to high risk HPV 16 (64 %)* 7 (12.7 %)*
Heterosexuals without warts: HIV-positive (n = 93) HIV-negative (n = 98)
antibodies to low risk HPV 15 (16.1 %) 12 (12.2 %)
antibodies to high risk HPV 29 (31.1 %)** 11 (11.2 %)**
Homosexuals without warts: HIV-positive (n = 50) -
antibodies to low risk HPV 15 (30%) -
antibodies to high risk HPV 21 (42%) -
Male blood donors: - HIV-negative (n = 100, STD history unknown)
antibodies to low risk HPV - 9 (9 %)
antibodies to high risk HPV - 10 (10 %)
  1. In HIV-positive men preferentially the high risk antibody prevalence is increased: + p = 0.2, *p < 0.0001, Odds ratio (95% CI), 12.2 (3.9–38.1); **p = 0.0007, Odds ratio (95%), 3.6 (1.7–7.7)